NASDAQ:VIVE

Viveve Medical Competitors

$3.12
-0.13 (-4.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.10
Now: $3.12
$3.25
50-Day Range
$2.91
MA: $3.29
$4.15
52-Week Range
$2.54
Now: $3.12
$14.40
Volume231,158 shs
Average Volume2.04 million shs
Market Capitalization$32.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59

Competitors

Viveve Medical (NASDAQ:VIVE) Vs. MDT, VAR, MASI, LIVN, CNMD, and INMD

Should you be buying VIVE stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Viveve Medical, including Medtronic (MDT), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD).

Viveve Medical (NASDAQ:VIVE) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Risk & Volatility

Viveve Medical has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Viveve Medical and Medtronic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viveve Medical00103.00
Medtronic031812.91

Medtronic has a consensus price target of $124.2692, suggesting a potential upside of 2.04%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Viveve Medical.

Valuation and Earnings

This table compares Viveve Medical and Medtronic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viveve Medical$6.57 million4.91$-42,530,000.00($338.00)-0.01
Medtronic$28.91 billion5.68$4.79 billion$4.5926.53

Medtronic has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

18.2% of Viveve Medical shares are owned by institutional investors. Comparatively, 79.2% of Medtronic shares are owned by institutional investors. 5.0% of Viveve Medical shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Viveve Medical and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viveve Medical-661.57%-243.62%-139.23%
Medtronic12.69%9.71%5.30%

Summary

Medtronic beats Viveve Medical on 13 of the 15 factors compared between the two stocks.

Viveve Medical (NASDAQ:VIVE) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Institutional and Insider Ownership

18.2% of Viveve Medical shares are owned by institutional investors. Comparatively, 87.0% of Varian Medical Systems shares are owned by institutional investors. 5.0% of Viveve Medical shares are owned by company insiders. Comparatively, 0.8% of Varian Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Viveve Medical and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viveve Medical-661.57%-243.62%-139.23%
Varian Medical Systems8.50%18.45%8.08%

Risk & Volatility

Viveve Medical has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Valuation and Earnings

This table compares Viveve Medical and Varian Medical Systems' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viveve Medical$6.57 million4.91$-42,530,000.00($338.00)-0.01
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.30

Varian Medical Systems has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Viveve Medical and Varian Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viveve Medical00103.00
Varian Medical Systems35001.63

Varian Medical Systems has a consensus price target of $159.3571, suggesting a potential downside of 10.03%. Given Varian Medical Systems' higher possible upside, analysts plainly believe Varian Medical Systems is more favorable than Viveve Medical.

Summary

Varian Medical Systems beats Viveve Medical on 11 of the 14 factors compared between the two stocks.

Viveve Medical (NASDAQ:VIVE) and Masimo (NASDAQ:MASI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Insider & Institutional Ownership

18.2% of Viveve Medical shares are owned by institutional investors. Comparatively, 81.6% of Masimo shares are owned by institutional investors. 5.0% of Viveve Medical shares are owned by company insiders. Comparatively, 11.5% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Viveve Medical and Masimo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viveve Medical-661.57%-243.62%-139.23%
Masimo20.30%15.75%13.12%

Risk & Volatility

Viveve Medical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Masimo has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Earnings & Valuation

This table compares Viveve Medical and Masimo's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viveve Medical$6.57 million4.91$-42,530,000.00($338.00)-0.01
Masimo$937.84 million13.83$196.22 million$3.2272.89

Masimo has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Viveve Medical and Masimo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viveve Medical00103.00
Masimo02502.71

Masimo has a consensus price target of $272.20, suggesting a potential upside of 15.97%. Given Masimo's higher possible upside, analysts clearly believe Masimo is more favorable than Viveve Medical.

Summary

Masimo beats Viveve Medical on 13 of the 14 factors compared between the two stocks.

Viveve Medical (NASDAQ:VIVE) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Insider & Institutional Ownership

18.2% of Viveve Medical shares are owned by institutional investors. Comparatively, 89.1% of LivaNova shares are owned by institutional investors. 5.0% of Viveve Medical shares are owned by company insiders. Comparatively, 0.5% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Viveve Medical and LivaNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viveve Medical-661.57%-243.62%-139.23%
LivaNova-21.88%5.55%3.07%

Risk & Volatility

Viveve Medical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares Viveve Medical and LivaNova's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viveve Medical$6.57 million4.91$-42,530,000.00($338.00)-0.01
LivaNova$1.08 billion3.64$-155,180,000.00$3.0826.30

Viveve Medical has higher earnings, but lower revenue than LivaNova. Viveve Medical is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Viveve Medical and LivaNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viveve Medical00103.00
LivaNova04202.33

LivaNova has a consensus price target of $67.50, suggesting a potential downside of 16.67%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than Viveve Medical.

Summary

LivaNova beats Viveve Medical on 9 of the 14 factors compared between the two stocks.

Viveve Medical (NASDAQ:VIVE) and CONMED (NYSE:CNMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Viveve Medical and CONMED, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viveve Medical00103.00
CONMED02402.67

CONMED has a consensus price target of $104.60, suggesting a potential downside of 22.19%. Given CONMED's higher possible upside, analysts clearly believe CONMED is more favorable than Viveve Medical.

Risk & Volatility

Viveve Medical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Profitability

This table compares Viveve Medical and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viveve Medical-661.57%-243.62%-139.23%
CONMED0.04%9.48%3.75%

Insider & Institutional Ownership

18.2% of Viveve Medical shares are owned by institutional investors. 5.0% of Viveve Medical shares are owned by company insiders. Comparatively, 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Viveve Medical and CONMED's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viveve Medical$6.57 million4.91$-42,530,000.00($338.00)-0.01
CONMED$955.10 million4.07$28.62 million$2.6450.92

CONMED has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats Viveve Medical on 10 of the 14 factors compared between the two stocks.

InMode (NASDAQ:INMD) and Viveve Medical (NASDAQ:VIVE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Profitability

This table compares InMode and Viveve Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMode32.57%28.56%24.14%
Viveve Medical-661.57%-243.62%-139.23%

Institutional & Insider Ownership

35.7% of InMode shares are held by institutional investors. Comparatively, 18.2% of Viveve Medical shares are held by institutional investors. 5.0% of Viveve Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

InMode has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for InMode and Viveve Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMode00403.00
Viveve Medical00103.00

InMode currently has a consensus price target of $71.50, suggesting a potential downside of 13.63%. Given InMode's higher probable upside, equities analysts clearly believe InMode is more favorable than Viveve Medical.

Earnings & Valuation

This table compares InMode and Viveve Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$156.36 million16.93$61.15 million$1.6051.74
Viveve Medical$6.57 million4.91$-42,530,000.00($338.00)-0.01

InMode has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Summary

InMode beats Viveve Medical on 12 of the 13 factors compared between the two stocks.


Viveve Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$121.79-0.2%$164.18 billion$28.91 billion46.48
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.12-0.1%$16.27 billion$3.17 billion60.45News Coverage
Masimo logo
MASI
Masimo
1.6$234.71-0.2%$12.97 billion$937.84 million60.96Insider Selling
LivaNova logo
LIVN
LivaNova
1.5$81.00-1.2%$3.94 billion$1.08 billion-18.84
CNMD
CONMED
1.6$134.43-0.3%$3.89 billion$955.10 million-3,360.75
InMode logo
INMD
InMode
1.5$82.78-2.5%$2.65 billion$156.36 million59.55
Outset Medical logo
OM
Outset Medical
0.9$55.61-4.9%$2.38 billionN/A0.00
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$34.80-3.4%$1.16 billion$27.37 million-47.67
NTUS
Natus Medical
1.1$26.09-0.0%$883.77 million$495.52 million-47.44
AxoGen logo
AXGN
AxoGen
1.5$19.74-1.6%$804.84 million$106.71 million-31.33
TransMedics Group logo
TMDX
TransMedics Group
1.6$28.61-11.0%$783.06 million$23.60 million-20.44Insider Selling
ViewRay logo
VRAY
ViewRay
1.3$4.17-2.9%$670.54 million$87.78 million-4.69
Cutera logo
CUTR
Cutera
1.3$31.54-0.4%$560.88 million$181.71 million-17.43
Zynex logo
ZYXI
Zynex
1.8$15.30-2.3%$533.28 million$45.47 million46.36News Coverage
Edap Tms logo
EDAP
Edap Tms
1.3$8.81-3.7%$256.74 million$50.23 million-146.83
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.65-2.4%$201.11 million$3.38 million-4.53
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.35-5.1%$138.29 millionN/A0.00
FONR
FONAR
1.1$18.01-3.4%$118.04 million$85.69 million16.99
IRIDEX logo
IRIX
IRIDEX
0.9$7.22-1.1%$112.06 million$43.45 million-13.13
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.35-8.1%$97.76 million$10,000.00-1.28
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.12-8.0%$89.29 millionN/A-1.47
electroCore logo
ECOR
electroCore
1.4$1.83-7.1%$88.71 million$2.39 million-2.32
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.28-3.4%$39.93 million$1.50 million-0.99
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.35-0.9%$32.30 million$5.51 million-0.11
STRR
Star Equity
0.1$3.24-1.9%$15.95 million$114.18 million-1.03
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.